Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by KingWhatsion Dec 13, 2010 12:48pm

339 Views

Post# 17838596

RE: RE: RE: No news....thus far

Perfect jocotoco. That way you pay tax this year on the gains then in the future you will pay tax on it again. Sure fired way not to get rich.

Me, I sell my junior at a loss into my TFSA and then reap the profit tax free. That way I get the tax loss for this year and tax free profits to live on next year.

Of course my way may be wrong. LOL

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX